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Chagas disease (CD), also known as American trypanosomiasis, is caused by the flagellated protozoan Trypanosoma
cruzi, and affects an estimated 8 to 10 million people worldwide. In Latin America, 25 million people live in risk
areas, while in 2008 alone, 10,000 CD-related deaths were reported. This review aimed to evaluate the challenges
of CD control, future perspectives, and actions performed worldwide to control expansion of the disease and its
impact on public health in Latin America.
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Chagas disease (CD), also known as American trypanosom-
iasis, is caused by the flagellated protozoan Trypanosoma
cruzi, and affects an estimated 8 to 10 million people
worldwide [1]. In Latin America, 25 million people live
in risk areas whereas, in 2008 alone, 10,000 CD-related
deaths were reported. The incidence of the disease is high
in rural areas where environmental conditions favor the
installation and breeding of triatomine bugs [2].
In the 1970s, 100,000 new cases of CD were recorded per
year in Brazil. This annual rate decreased to 10,000 after
the implementation of effective campaigns for the control
of vector transmission (the main route of acquisition of the
disease). Today, about 3 million people are estimated to be
infected, but this number could be much higher since most
individuals do not exhibit symptoms and are classified as
carriers of the indeterminate form of CD [3].
This review aimed to evaluate the challenges of CD
control, future perspectives, and actions performed world-
wide to mitigate expansion of the disease and its impact
on public health in Latin America.
Review
Mechanisms of transmission
The two main transmission routes of CD include common
and uncommon or accidental transmission. The most* Correspondence: ppereira@fmb.unesp.br
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bugs), transfusion (transfusion of blood contaminated
with T. cruzi), oral transmission (ingestion of foods or
beverages contaminated with triatomine feces), and vertical
or congenital transmission (parasite crossing the placental
barrier). Uncommon or accidental modes of transmission
include transmission during organ transplantation, inges-
tion of maternal milk contaminated with the protozoan,
laboratory accidents, contamination of foods with secre-
tions from the anal glands of marsupials harboring the
parasite, bites of contaminated arthropods (demonstrated
experimentally), and sexual relations (contamination of
men who have had sexual contact with infected women
during their menstrual period) [4].
Vector transmission is the classical form of CD acqui-
sition. This transmission route has the largest impact in
Latin American countries and is also responsible for the
maintenance of the disease. In this case, the insect vector
is contaminated by feeding on the blood of an infected
host and defecates at the site of the bite wound. Parasites
then enter the bloodstream and invade cells of the mono-
phagocytic system. Another possibility of transmission is
contamination of the proboscis of the vector with its
own feces or with feces from another contaminated
vector [4,5] (Additional file 1 http://www.youtube.com/
watch?v=1ais69H0li8).
The following triatomine species can transmit CD:
Triatoma sordida, Triatoma pseudomaculata, Triatoma
tibiamaculata,Triatoma arthurneivai,Triatoma brasiliensis,
Triatoma dimidiata, Panstrongylus megistus, PanstrongylusCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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nius prolixus, Rhodnius megistus, and Rhodnius domesticus.
However, the main species related to CD transmission
in Brazil is Triatoma infestans [6].
In the 1950s, the Brazilian government implemented
vector control campaigns in some regions of the country;
however, only in the 1980s were these campaigns extended
to the whole territory. In 1991, the National Health Foun-
dation (FUNASA) assumed the control of all endemic
diseases. At the same time, the South American countries
where two-thirds of CD carriers in the Americas are
concentrated (Argentina, Brazil, Chile, Uruguay, Paraguay,
Bolivia and Peru) started an international cooperation
program, the South Cone Initiative, whose objective was
to control the vector and transfusion transmission [7-9].
The success of the campaigns for vector eradication was
so impressive that some countries have been certified free
of vector transmission, including Uruguay (1997), Chile
(1999), and Brazil (2006). The Pan American Health
Organization (PAHO) certificate declaring an area free
of transmission of the Triatoma infestans vector does not
signify complete interruption of transmission, but rather
effective control [10-12]. Furthermore, improvement in
the socioeconomic conditions of the Brazilian population
in recent decades has provided dwellings that were less
favorable to transmission of the vector, thus contributing
to the control of this disease.
Another goal achieved by the South Cone Initiative
was the mandatory serological screening of blood banks,
including 100% of public blood banks and 80% of private
blood banks in Argentina, and all blood banks in Brazil,
Chile and Uruguay. On the other hand, Paraguay, Bolivia
and Peru continue to fight against the disease, but have
not yet reached the targets of the program [8].
A number of studies involving blood donors from the
whole country have been conducted in an attempt to
determine the seroprevalence of chagasic infection in
Brazil. Sobreira et al. [13] studied 3,232 blood donors
from the Iguatu Blood Center (Ceará state) and found
that 61 (1.9%) presented serology positive for CD. At the
São Lucas Hospital of the Pontifical Catholic University of
Rio Grande do Sul, 8,228 samples were tested by different
methods (ELISA, hemagglutination and indirect immu-
nofluorescence) and revealed a seroprevalence ranging
from 0.4 to 0.5% [14]. In another study conducted in Rio
Grande do Sul state, Fitarelli and Horn [10] observed that
the prevalence of CD in the southern region was lower than
the national average (0.41% versus 0.61%). Silva and Silva
[15] found a CD seroprevalence of 1.2% at the Hemominas
Foundation (Patos de Minas, Minas Gerais state).
A major problem encountered in seroprevalence studies
was the high incidence of inconclusive serological reac-
tions. At the Blood Center of Pernambuco (Hemope),
743,529 blood donations made between 2002 and 2007were evaluated; of these, 1,264 were negative for CD,
including 39.7% reactive samples and 60.3% inconclusive
samples [16]. At the Uberaba Blood Center, 52% of all
non-negative serological reactions were inconclusive
[17]. Navarro et al. [18], while analyzing non-negative
serological reactions at the Botucatu Blood Center, found
0.5% non-negative and 35.4% inconclusive.
Picka et al. [19] investigated inconclusive serological
reactions by different methods (ELISA, indirect hemag-
glutination, indirect immunofluorescence and TESA-cruzi
immunoblotting) and concluded that TESA-cruzi is the
best method to confirm positive serology in individuals
with more than two inconclusive reactions.
The success of vector transmission control can be
observed in the studies cited above and corroborates
data reported by Dias [20] and Moraes-Souza et al. [21]
showing a reduction in the seroprevalence of CD among
blood donors from 7 to 0.6% between 1970 and 2006.
Oral transmission has gained much attention in the past
decade. Until 2004, few CD-related studies on contami-
nated foods and beverages have been published. However,
after an initial outbreak that occurred in the state of Santa
Catarina in 2005, new outbreaks have been reported,
especially in the northern region where the consumption
of fresh açaí berries is frequent. In the state of Pará alone,
oral transmission was responsible for 178 cases of the
acute form of CD in 2006. As a consequence, the Brazilian
authorities implemented guidelines of good manufacturing
practices and mandatory pasteurization of beverages and
foods related to the oral transmission of CD [22].
In countries with currently successful vector control,
congenital or vertical transmission has become the focus
of attention. Although the congenital transmission rate
is low (4-8%), it may be responsible for maintaining the
transmission cycle among young individuals, particularly
among women of childbearing age [23].
Over the last two decades, congenital transmission has
received special attention in different countries that are
not endemic for CD, since various cases were diagnosed
in Latin American women. In light of the migration of
Latin American women to European countries and to
North America, some countries – including Spain and
USA – have established serological screening of pregnant
women for CD in some cases. In Brazil, only a few studies
on CD in pregnant women are available. Furthermore,
serological screening for CD is not part of routine prenatal
care, even in historically endemic areas.
In a study conducted at seven hospitals in Madrid,
Spain, involving 3,839 pregnant Latin American women,
the seroprevalence of CD was 3.96% and the rate of con-
genital transmission was 2.6%, demonstrating the impact
of this route of transmission [24].
Romero et al. [25] studied 1,730 women of childbearing
age from the rural population of Carapari, Bolivia, and
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examination of 468 newborns of seroreactive women
found a congenital transmission rate of 4% (12/299). To
confirm the diagnosis of congenital transmission, the
infants were monitored up to 12 months of age, since
maternal IgG antibodies transferred through the placenta
can be present until 7 months of age.
Araujo et al. [26] conducted an epidemiological study of
CD involving pregnant women from the Brazilian town of
Pelotas (Rio Grande do Sul state). A total of 351 umbilical
cord serum samples obtained from the parturients were
analyzed and only one case was positive. For screening
purposes, samples were collected from all household
members and animals living in the residence of the
infected mother and only the mother was seroreactive.
The women reported having received a blood transfu-
sion during childhood, which probably was the route of
transmission.
According to some studies, congenital transmission is
due to large quantities of circulating parasites in maternal
blood before delivery. Reduced interferon gamma (IFN-γ)
production during pregnancy is related to higher rates
of contaminated neonates in contrast to higher mono-
cyte activation in the mothers who did not transmit the
parasite to their children [27,28]. As a consequence,
congenital transmission is directly related to maternal
parasite burden.
According to Fretes and Kemmerling [29], during preg-
nancy the maternal immune system potentiates cellular
and molecular recognition, cell-to-cell communication,
and cell repair in order to protect the fetus whose immune
system is still developing [28]. Nevertheless, the maternal
immune system is not always efficient. Duaso et al. [30]
showed that apoptosis is a normal event during pregnancy
as part of placental tissue renewal, eliminating undesired
cells such as inflammatory cells. However, in women in-
fected with T. cruzi, apoptosis may affect healthy cells and
favor the passage of the parasite through chorionic villi.
Brutus et al. [31] studied 513 mothers and 516 infants
from Bermejo (southern Bolivia) where vector transmission
is absent and observed a CD prevalence of 33.9% among
mothers, particularly those aged 26 to 35 years. In that
study, the congenital transmission rate was 5.2%, but the
severity of the disease was low in these infants.
Since 1987, the World Health Organization (WHO) has
recommended preventive chemotherapy (benznidazole or
nifurtimox) for pregnant women with CD despite its high
toxicity, to reduce parasite burden as well as the risk of
congenital transmission [27].
According to Bern and Montgomery [32], the control of
congenital transmission is the main measure for prevent-
ing CD in countries where insect vectors are absent.
A study involving all pregnant women seen at three
maternity wards in Santa Cruz de la Sierra (westernBolivia) was conducted to determine congenital trans-
mission rates. The Stat-Pak Assay®, a rapid test for the
diagnosis of CD, and a third-generation ELISA (Chagatest®)
were used. A total of 257 newborns, including 111 infected
infants of seroreactive mothers, 68 negative infants born
to positive mothers and 78 negative neonates of negative
mothers, were studied. All newborns with confirmed
positive serology were treated with benznidazole and
presented negative serology after 6 months, demonstrating
the efficacy of treatment during the acute phase [33].
Some Latin American countries such as Paraguay,
Uruguay and some regions in Argentina have already
implemented prenatal screening for CD. In Brazil, screen-
ing of pregnant women is not part of the national program;
however, the Association of Parents and Friends of Ex-
ceptional Children (APAE) performs screening tests for
CD in the states of Mato Grosso do Sul and Goiás [34].
According to De Rissio et al. [35] control measures of
congenital transmission should be established as a public
health priority in all endemic regions and for pregnant
women originating from these areas, since evidence indi-
cates congenital transmission to be the current main mode
of transmission that may lead to global dissemination
of the disease.
The diagnosis of congenital transmission is important
for public health since, although diagnosed pregnant
women tend to be in the chronic symptomatic or
asymptomatic phase for which no proven effective
treatment exists, their children are in the acute phase
for which treatment and a definitive cure are available.
According to González-Tomé et al. [23] an estimated 2
million women of childbearing age are infected with
the protozoan T. cruzi in the Americas while the rate
of congenital transmission ranges from 4 to 8%; thus,
the number of infected children may reach 15 million.
Determinants of infection
One of the main determinants of T. cruzi infection is the
initial inoculum. The different triatomine species that
can transmit CD show distinct patterns of parasite elim-
ination in feces. Borges-Pereira et al. [36] evaluated eight
triatomine species infected with T. cruzi during feeding
and observed an average of 40 parasites per evacuation.
When the mean number of parasites eliminated per
species was analyzed, P. megistus was found to be the
most effective (232) and T. pseudomaculata the least
effective (51 parasites).
Some decades ago, reinfection was another problem
encountered in historically endemic areas such as the
interior of the states of Minas Gerais, Pernambuco and
São Paulo, which was mainly due to precarious housing
conditions that favored the infestation of dwellings and
attracted triatomine bugs to peridomestic areas. Today,
this is an important characteristic of the Brazilian Amazon
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and vectors) and social determinants (intense internal
migration) favor the introduction of multiple parasite
strains. Over the last 300 years, human invasion of wild
environments, deforestation and cattle farming have
favored the establishment of domestic and peridomestic
cycles [37]. There are few reports of patients with
chronic CD in these regions, but more than 100 cases
of the acute form of the disease have been registered,
particularly cases of oral transmission [38,39].
Until the 1980s, T. cruzi strains were subdivided into
three groups (zymodemes): I, II and Z3, with groups I
and Z3 (III) including wild strains and group II including
domestic strains. With the advances in molecular biology
techniques, it can now be confirmed that the parasite
presents a great genetic diversity and can be classified
into six discrete typing units, which possess common
immunological and molecular markers. Strains I (wild)
and II (domestic) are pure and strains III to VI are
hybrids [40,41].
The initial immune response of the host seems to be
crucial for the clinical progression of CD. Some authors
defend the proposition that the initial increase in IFN-γ,
followed by an increase in IL-10 (both cytokines produced
by CD4+ lymphocytes), is responsible for the clinical
course of the indeterminate form of the disease [42,43].Clinical phases
The incubation period of T. cruzi ranges from 3 to
112 days depending on the mode of infection [44].
The acute phase lasts 4–8 weeks and is generally
asymptomatic or oligosymptomatic. In the latter case,
the disease manifests as a self-limited febrile illness
whose symptoms may occur 1 to 2 weeks after vector
contamination or within a few months after transfusion
of contaminated blood. In symptomatic cases, prolonged
fever, malaise, hepato- and/or splenomegaly, lymphadeno-
megaly, localized or generalized subcutaneous edema,
and signs at the site of parasite entry (Romaña’s sign or
chagoma inoculation) are observed. Cardiac and neuro-
logical alterations are rare. The mortality rate ranges from
5 to 10% in acute cases, generally involving children who
die of myocarditis and/or myeloencephalitis [40,45].
Most acute cases of CD in Brazil are registered in the
northern states, but there are still sporadic reports of
acute cases in the southeastern region of the country.
In 2006, a 6-year-old child living in the rural area of
Itaporanga died after 27 days of nonspecific symptoms
and erroneous diagnoses. This case illustrates why CD is
considered the most neglected of the neglected tropical
diseases since, although this child lived in a historically
endemic area for CD, at no time was the diagnosis of
the acute phase taken into consideration [46].In a study conducted at the University Hospital of
Botucatu, Geraix et al. [47] observed that more than
70% of patients with CD had the indeterminate form,
followed by the digestive, cardiac and mixed form [46].
The course of the chronic form of the disease is variable,
with about 60% of parasitized individuals presenting
the indeterminate form (no symptoms) and 20 to 40%
developing the cardiac and/or digestive form [48].
The indeterminate form of CD shows the best clinical
prognosis for chronic patients, since there is serological
demonstration of the presence of the parasite but no car-
diac or digestive involvement, a course that can continue
until the end of life. The main problem encountered by
physicians and patients in these cases is the uncertainty.
It is very common that the patient believes his heart
will “swell” at any time and that he will lose the capacity
to perform daily activities. Since there is no safe marker
of disease progression, this difficult situation is likely to
continue.
According to Maya et al. [49] there are four main
mechanisms underlying the pathogenesis of the cardiac
form of CD: parasite-induced myocardial damage, im-
mune-mediated myocardial damage, cardiac dysautonomia,
and cardiovascular anomalies and ischemia.
In an experimental study, Coura [50] demonstrated a
reduction in cardiopathy when animals were treated with
anti-trypanosomatid drugs in order to reduce parasite
burden. The author showed that parasite persistence in host
tissues plays an important role in myocardial aggression.
According to Marin-Neto et al. [51] the cardiac form of
CD is characterized by inflammatory infiltration, cell death
and reparative interstitial fibrosis, events that lead to
disturbances in the cardiac conduction system (intra-
ventricular and atrioventricular blockade, sinus node
dysfunction, and ventricular arrhythmia) and myocarditis,
causing electrical instability (atrial arrhythmia), reduced
contractility (intracavitary thrombosis and heart failure)
and microvascular disturbances (tip aneurism) which can
result in sudden death. Alterations in the intracardiac
nervous system can cause atypical chest pain and also
sudden death.
Digestive problems are observed in one-third of chagasic
patients and usually result in dilatation of the gastro-
intestinal tract. According to Lescure et al. [52] the
digestive form is responsible for the development of
mega-syndromes of the esophagus (dysphagia, chest
pain, and regurgitation) and colon (chronic constipation,
abdominal pain, and obstruction). Involvement of the
esophagus includes the loss of esophageal peristalsis
and lack of relaxation of the lower sphincter during
swallowing, impairing deglutition and causing progressive
dilatation of the organ. Esophageal dysfunction may also
be associated with alterations in intestinal transit. This
form of the disease is characterized by the destruction
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transit, leading to muscle hypertrophy and, in more
exacerbated cases, to dilatation of the organ [53].
According to Oliveira et al. [54], there are an estimated
300,000 individuals with megacolon, the main symptoms
of which are constipation and fecal impaction. Silva et al.
[55], reported alterations in intestinal secretion, absorption
and motility in these patients, which culminate in mega-
syndromes (dilated area upstream from the achalasic
segment). Patients with megacolon can also present chronic
constipation, abdominal pain, volvulus, obstructions, and
intestinal perforations.Diagnosis
The clinical diagnosis of CD can only be confirmed during
the acute phase if there are signs of parasite entry such as
Romaña’s sign and/or inoculation chagoma. This phase is
characterized by high parasitemia, a fact that permits a
parasitological diagnosis. The thick drop test has been
frequently used in epidemiological field studies due to its
low cost and easy visualization of the parasite; however,
rapid serological tests such as the Stat-Pack assay have
attracted the attention of researchers since they permit a
diagnosis of chronic carriers of the disease [33].
The chronic phase of CD is characterized by low parasit-
emia, which hampers the efficiency of direct identification
of the parasite. Therefore, other methods – namely para-
sitological (xenodiagnosis), serological (ELISA, indirect
hemagglutination, indirect immunofluorescence, chemi-
luminescence, and TESA-blot), and molecular biology
(PCR) – are used during this phase.
The xenodiagnosis technique was introduced by Brumpt
in 1914 (natural xenodiagnosis) and consists of the direct
application of triatomine nymphs on the skin surface,
which caused discomfort and refusal of the patients to
undergo this test. In the 1940s, Romana and Gil introduced
artificial xenodiagnosis, which avoids direct contact of the
individual with the bug [19].
ELISA has been used for many years as the gold stand-
ard for diagnosing CD. In this method, T. cruzi-specific
antigens are fixed on an ELISA plate (sensitization phase).
Next, the patient serum is incubated with a primary anti-
body, followed by incubation with a conjugated antibody
for the formation of an immunocomplex. Finally, a chromo-
gen solution is added to the reaction for color production,
which can be analyzed in an ELISA reader at a given wave-
length [56].
The chemiluminescence test is an enzyme immunoassay
for the qualitative detection of anti-T. cruzi IgG antibodies.
The test requires two steps: samples and diluents are
mixed with paramagnetic microparticles coated with
recombinant T. cruzi antigens (FP3, FP6, FP10, and TcF);
then, human IgG antibodies are labeled with acridine andthe chemiluminescence reaction is measured in relative
light units.
Indirect hemagglutination was introduced by Cerisola
et al. [57]. This method uses stabilized bird erythrocytes
that are sensitized by binding to highly purified T. cruzi
antigens. Agglutination is observed when these antigens
react with antibodies present in the patient’s serum. The
reaction is defined as positive when the red blood cells
settle in the bottom of the microplate well, forming a
uniform network that is sometimes partially retracted at
the borders [19].
The TESA-blot is a Western blot method that uses
TESA (antigens excreted from trypomastigotes) and T.
cruzi strain Y (TESA-blot). Positive reactions are indicated
by the presence of bands at a molecular weight of 120–
200 kDa [19].
Blood culture uses liver-infusion tryptose (LIT) medium
for the incubation of a patient’s blood. The culture is
analyzed for up to 180 days and the observation of flagel-
late forms of T. cruzi is defined as a positive result [58].
Treatment
Chagas disease is considered the most neglected of the
neglected tropical diseases, a fact that can be demonstrated
within the context of treatment. In the 1970s, two drugs
that act by forming free radicals and/or electrophilic
metabolites were made available on the market. In Brazil,
only benznidazole is currently used and its efficacy is
observed during the acute phase of CD [59]. The lack
of effective drugs for treatment of the chronic phase,
particularly the chronic indeterminate form, has brought
anguish for patients and their doctors who have taken care
of them for decades. Benznidazole acts through three
effector mechanisms: trypanocidal action (formation of
covalent bonds with T. cruzi macromolecules such as
DNA and cytochrome P450); increase in phagocytosis and
parasite lysis through an IFN-γ-dependent mechanism;
and, finally, inhibition of parasite growth by blocking
NADH-fumaratereductase. Despite its efficacy in the
treatment of the acute phase, benznidazole has several side
effects ranging from hypersensitivity reactions to bone
marrow depression and peripheral polyneuropathy [60].
Among the new drugs being tested, some are already
in clinical trials. One of these drugs, posaconazole, has
shown promising results in the treatment of patients in
the acute and chronic phase. This drug was found to be
effective in eliminating amastigotes from cardiac cells.
Some studies have used combinations of drugs such as
benznidazole, nifurtimox, benznidazole and allopurinol,
among others [61].
The research group of the School of Medicine of
Ribeirão Preto (FMRP/USP) is developing new drug
candidates based on the capacity of nitric oxide to kill
the parasite [62]. Guedes et al. [63] tested treatment
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and demonstrated that this drug induces the release of
nitric oxide inside macrophages, exerting a significant
trypanocidal effect [63]. When administered in combin-
ation with benznidazole, this substance prevents death by
reducing parasitemia and cardiac inflammation. Another
study conducted by the same group used cis-[Ru(NO)(bpy)
2 L]Xn and showed that the drug exerts a more effective
trypanocidal activity at a lower dose than benznidazole [64].
Despite progress in the identification of new drug
candidates against CD, the therapeutic proposal has
remained the same for more than 40 years and there is no
effective treatment for the chronic phase of the disease.
Conclusions
Several Latin American countries have joined efforts to
control the different routes of CD transmission, but an
effective control in the Americas is still a distant dream.
In Brazil, the control of vector and transfusion transmission
has been shown to be effective, but serological screening
of pregnant women from historically endemic areas for
CD is not yet mandatory.
Another important step related to CD is the develop-
ment of new drugs. The two currently available drugs
(benznidazole and nifurtimox) are effective in treating
the acute phase of the disease, but not the chronic phase.
In addition, the side effects of these drugs are severe and
are responsible for the fact that many patients abandon
treatment. One of the main achievements in CD treatment
was the development of dispersible tablets that are
used for treating children, since in the past the parents
had to fractionate the medication into as many as 12
parts, favoring treatment failure due to incorrect doses.
The pediatric medication is produced exclusively by the
Pharmaceutical Laboratory of the state of Pernambuco
(LAFEPE, Brazil) supported by the Drugs for Neglected
Disease Initiative (DNDi).
Another important national achievement is being made
by researchers at FMRP, where a new drug consisting
of a combination of benznidazole and nitric oxide is
being patented. In addition to reducing the parasite
burden in mice, this drug has been shown to increase
survival by 100%.
Immunological studies are being conducted at various
universities around the world in an attempt to understand
the immune response of patients with indeterminate CD,
since parasitemia is maintained under control in these
patients. A precise understanding of these mechanisms
may contribute to the development of new drugs. At
the Botucatu Medical School (FMB/UNESP), various
research groups from different fields are studying CD. The
authors of the present study are part of the research group
at the Laboratory of Tropical Diseases of FMB, where
immunological, molecular and metabolic aspects of thedisease are investigated. At present, one of the groups is
analyzing the relationship of the lipid profile and nutri-
tional status of patients with CD with proinflammatory
cytokines and nitric oxide. Preliminary results are available
and will be published soon.
Although CD is a centuries-old disease and many efforts
have been made in Brazil to control the main routes of
transmission, many aspects remain unclear, a situation
that requires further studies, particularly those focusing
on immunological aspects and on investigating new
drugs. Albeit successful measures have been established
in Brazil, there are still cases of young individuals with
CD. Hence, the price of maintaining these achievements
will be eternal vigilance.
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